Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

NCT02987400 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: Venetoclax
DRUG: Obinutuzumab

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators

[object Object]